Clinical Trial Update: Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Belimumab to mobilize memory B-cells and improve HLA-specificity profiling for delisting to access transplanted kidneys in highly-sensi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Kidney Transplant Rejection | Phase 2 | Status: NOT_YET_RECRUITING